CLAIMS

1. Use of a composition comprising (i) an antagonist of a Programmed Death 1 protein (PD-1), wherein the PD-1 antagonist is pembrolizumab, and (ii) eribulin or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of triple negative breast cancer in an individual.

2. The use of claim 1, wherein the individual is a human.

3. The use of claim 1 or 2, wherein the triple negative breast cancer is metastatic.

4. The use of any one of claims 1 to 3, wherein the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

5. A medicament comprising:

(a) a combination of an antagonist of a Programmed Death 1 protein (PD-1) and eribulin, wherein the PD-1 antagonist is pembrolizumab; or

(b) a combination of an antagonist of a Programmed Death 1 protein (PD-1) and a pharmaceutically acceptable salt of eribulin for use in treating triple negative breast cancer in an individual, wherein the PD-1 antagonist is pembrolizumab.

6. The medicament of claim 5, wherein the individual is a human.

7. The medicament of claim 5 or 6, wherein the triple negative breast cancer tests positive for PD-Ll expression by an immunohistochemical (IHC) assay.

8. The medicament of any one of claims 5 to 7, wherein the breast cancer is metastatic.

9. The medicament of any one of claims 5 to 8, wherein the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

10. The medicament of claim 9, wherein pembrolizumab is formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v)

polysorbate 80 in 10 mM histidine buffer pH 5.5, and eribulin or a pharmaceutically acceptable salt thereof is formulated as a liquid medicament which comprises 0.5 mg/mL eribulin mesylate or a pharmaceutically acceptable salt thereof.

11. A kit comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), wherein the PD-1 antagonist is pembrolizumab, the second container comprising at least one dose of a medicament comprising eribulin or a pharmaceutically acceptable salt thereof, and a package insert comprising instructions for treating an individual for triple negative breast cancer using the medicament.

12. The kit of claim 11, wherein the individual is a human.

13. The kit of claim 11 or 12, wherein the PD-1 antagonist is pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5 and the pharmaceutically acceptable salt of eribulin is eribulin mesylate formulated as a liquid medicament which comprises 0.5 mg/mL eribulin mesylate.

14. The use of claim 1, wherein the eribulin or the pharmaceutically acceptable salt thereof is to be administered at a dose of 1.4 mg/m^2, 1.1 mg/m^2, or 0.7 mg/m^2 on days 1 and 8 of a 21-day cycle and pembrolizumab is to be administered at a dose of 200 mg Q3W.

15. The medicament of claim 9, wherein the eribulin mesylate is to be administered to the individual at a dose of 1.4 mg/m^2, 1.1 mg/m^2, or 0.7 mg/m^2 on days 1 and 8 of a 21-day cycle and pembrolizumab is to be administered to the individual at a dose of 200 mg Q3W.